LRMR — Larimar Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$3.98
+$0.04 (+1.02%)
Larimar Therapeutics Inc (LRMR) is a biotechnology company listed on NASDAQ. It is led by Carole S. Ben-Maimon M.D., based in Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004, with about 65 employees. Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Net income was -$103.2M. LRMR currently screens at market cap $204.9M.
Use this LRMR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LRMR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LRMR SEC filings page. Lician reads the product cache first so this HTML stays unique to Larimar Therapeutics Inc even when a live quote feed is slow.
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
LRMR Key Statistics
Market Cap
$204.89M
Volume
208,388
Previous Close
$4.16
Day Range
$4.02 – $4.16
EPS
-$1.32
Revenue
$0.00
Net Income
-$80.60M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
65
LRMR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$80.60M | -$36.95M | -$35.35M | -$50.64M |
| EPS (Diluted) | -$1.32 | -$0.84 | -$1.37 | -$2.95 |
Total Assets
$200.22M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$33.22M
Operating Cash Flow
-$70.76M
Free Cash Flow
$0.00
Larimar Therapeutics Inc Company Information
- CEO, President & Director
- Carole S. Ben-Maimon M.D.
- Headquarters
- Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004
- Website
- larimartx.com
- Phone
- 844-511-9056
- IPO / Founded
- 2014-06-19
- Sector
- Healthcare
- Industry
- Biotechnology